Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Asandeutertinib (TY-9591) in Advanced EGFR-Mutated NSCLC
NCT04204473Phase 1Completed
- Sponsor
- TYK Medicines
- Start
- May 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of asandeutertinib in non-small cell lung cancer (NSCLC), sponsored by TYK Medicines. Primary endpoints: Dose Limiting Toxicity, Maximum Tolerated Dose at 1 year and 2 more. Started May 2020; status: completed.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04204473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04204473.